Status:
TERMINATED
Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease
Lead Sponsor:
Oregon Health and Science University
Conditions:
Parkinson's Disease
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
Levodopa is the main drug treatment for Parkinson's disease. Levodopa can cause unwanted and uncontrolled movements called dyskinesias. A drug called amantadine can reduce these movements. To date, th...
Detailed Description
Nearly all Parkinson's disease (PD) patients eventually develop abnormal and unwanted movements (dyskinesias) caused by the gold standard treatment, Levodopa. The severity of these movements can range...
Eligibility Criteria
Inclusion
- Parkinson's Disease
- At least 21 years of age
- Must be taking Oral levodopa
- Must have dyskinesias by history or previous clinical observation
Exclusion
- Significant cognitive impairment as measured by the Montreal Cognitive Assessment (MOCA) score of \< 25
- Subjects with unstable medical or psychiatric conditions (including hallucinations)
- Use of dopamine receptor blocking medications (e.g., neuroleptics, certain antiemetics, tetrabenazine)
- History of unstable medical conditions (ie active cardiovascular disease, recent unwellness or surgery etc.)
- Use of anticoagulants
- Current substance abuse
- Previous adverse event on amantadine
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00794313
Start Date
September 1 2009
End Date
June 1 2010
Last Update
February 1 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health & Science University
Portland, Oregon, United States, 97239